


Serial No. 10/816,476
Attorney Docket No. VU60111 US

REMARKS

The specification has been amended to include a reference to U.S. Provisional Application No. 60/460,733, filed 4 April 2003, the benefit of which was claimed within the time period set forth in 37 CFR 1.78(a) in an oath or declaration, as well as in the application transmittal letter. Because the benefit claim was recognized by the Office (see the Continuity information found in the PAIR system for the present application), Applicants' submit that neither a petition nor surcharge under 37 CFR 1.17(t) is required. See MPEP § 201.11.V. In the event that the Office deems otherwise, Applicants hereby petition to file an unintentionally delayed claim and hereby state that the entire delay between the due date and the date the claim was made was unintentional.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:



Eric J. Kron
Attorney for Applicants
Reg. No. 45,941

Date: February 24, 2006
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988